Joshua Boger Net Worth, Age, Height, Bio, Birthday, Wiki!
Explore Joshua Boger net worth, age, height, bio, birthday, wiki, and salary! In this article, we will discover how old is Joshua Boger? Who is Joshua Boger dating now & how much money does Joshua Boger have?
Joshua Boger Biography
Joshua Boger is one of the most popular and richest Biochemist who was born on April 12, 1951 in Concord, United States. Joshua S. Boger was born on the 12th of April 1951, in Concord, North Carolina to Charles E. Boger, Jr. who was an industrial chemist in the field of textiles as well as Mary Snead Boger, an actor and writer.
Based on the advice from Max Tishler, Boger was appointed to work for Merck Sharp & Dohme Research Laboratories in the year 1978. He began his work on the development of hypertension medications, including an extremely potent renin antagonist. One of the most important steps in this development was the use computer-based modeling to the chemical aspects of the drug’s design.
In 1989, Boger founded Vertex Pharmaceuticals Incorporated. He has served variously as its President, CEO and Chairman of the board.
Vertex also developed Telaprevir, a protease inhibitor for treatment of hepatitis C. Telaprevir works by disabling a protein that the virus requires for replication. Scientists at Vertex first published the crystal structure for the protease of the hepatitis C virus in 1996. As part of the development process for the drug, the company developed an elaborate systems biology model in which they modeled hepatitis C’s dynamics to the level of individual patient response. Telaprevir was approved by the Food and Drug Administration as Incivek in May 2011.
Boger later attended Harvard University, where he worked alongside Jeremy R. Knowles on the Chemistry of the compound cyclodextrin. He earned his master’s degree in 1975 , and his doctorate degrees in Chemistry in 1979. He conducted postdoctoral research on molecular recognition in collaboration with Jean-Marie Lehn from the Universite Louis Pasteur in Strasbourg, France.
| Name | Joshua Boger |
| First Name | Joshua |
| Last Name | Boger |
| Occupation | Biochemist |
| Birthday | April 12 |
| Birth Year | 1951 |
| Place of Birth | Concord |
| Home Town | |
| Birth Country | United States |
| Birth Sign | Aries |
| Full/Birth Name | |
| Father | Not Available |
| Mother | Not Available |
| Siblings | Not Available |
| Spouse | Not Known |
| Children(s) | Not Available |
Ethnicity, religion & political views
Many peoples want to know what is Joshua Boger ethnicity, nationality, Ancestry & Race? Let's check it out! As per public resource, IMDb & Wikipedia, Joshua Boger's ethnicity is Not Known. We will update Joshua Boger's religion & political views in this article. Please check the article again after few days.
In 2000, Boger combined his interests in scuba diving and photography by photographing the coral reefs off Wakaya Island near Fiji. By 2014, he was showing his underwater photography in one-man gallery shows. A permanent exhibit of 22 photographs, “Wakaya Octocorals and Giants,” is on display at the Exley Science Center at Wesleyan University.
Joshua Boger Net Worth
Joshua Boger is one of the richest Biochemist from United States. According to our analysis, Wikipedia, Forbes & Business Insider, Joshua Boger's net worth $5 Million. (Last Update: December 11, 2023)
Joshua S. Boger (born on April 12, 1951) is an organic chemist as well as co-founder of Vertex Pharmaceuticals Incorporated. He is regarded as an innovator on the subject of rational structure-based drug design. The drugs he developed include amprenavir is which is an HIV protease inhibitor. Telaprevir which is a protease inhibitor to treat hepatitis C as well as Kalydeco for treatment of cystic fibrosis. The year 2003 was the time Vertex has been named one of the world’s forty technology pioneers in the World Economic Forum. In the year 2012 Boger has been named the executive director for Alkeus Pharmaceuticals.
Between 1970 and in 1973 Boger was a student at Wesleyan University. In this period, Max Tishler, formerly the director of Merck Sharp and Dohme Research Laboratories was Boger’s mentor. Boger earned his bachelor’s degree in the sciences of chemistry and philosophy at Wesleyan in 1973.
Within 2 years, Boger was leading a group at Merck where he developed novel rational drug design techniques and applied them to pharmaceutical discovery and development. By 1987 Boger became senior director of basic chemistry at Merck Sharp & Dohme Research Laboratories, in charge of the departments of Biophysical Chemistry and Medicinal Chemistry of Immunology and Inflammation.
| Net Worth | $5 Million |
| Salary | Under Review |
| Source of Income | Biochemist |
| Cars | Not Available |
| House | Living in own house. |
A third product, an orally administered pill for the treatment of cystic fibrosis, grew out of the acquisition of Aurora Biosciences Corporation by Vertex in 2001. The San Diego research company had a contract with the Cystic Fibrosis Foundation, a nonprofit for patient advocacy and research, to create an assay for the disease. After the acquisition, the Cystic Fibrosis Foundation approached Vertex about expanding the contract to search for a drug treatment. The potential market for such a drug was small, unlikely to return a profit. The problem required a new approach: finding a way to turn on a non-functioning protein. Boger’s decision to investigate a new area has been treated as a case study by the Harvard Business School. It is one of the first examples of venture philanthropy funding, in which a charity buys equity in a company, which then tries to solve a specific problem for them. Vertex has since developed several possible drugs for the treatment of cystic fibrosis, the first of which was Kalydeco in 2012.
Boger is a founding director and chairman of NEHI (Network for Excellence in Health Innovation), established in 2002. He is a founding director and vice-chairman of the Alliance for Business Leadership (formerly the Progressive Business Leaders Network), established in 2006. Boger is a member of the board of fellows of the Harvard Medical School.
Height, Weight & Body Measurements
Joshua Boger height Not available right now. Joshua weight Not Known & body measurements will update soon.
| Height | Unknown |
| Weight | Not Known |
| Body Measurements | Under Review |
| Eye Color | Not Available |
| Hair Color | Not Available |
| Feet/Shoe Size | Not Available |
Boger is an advocate of liberal education who has been strongly involved with his alma mater, Wesleyan University. Boger became a member of the board of trustees of Wesleyan University as of 1999, and chairman of the board of trustees as of 2009. On his retirement from the board of trustees in 2016, he and his family donated $20 million to Wesleyan, over half of which established an endowed scholarship program.
At Vertex, Boger pioneered an approach to structure-based rational drug design that changed the way that drug development occurred. The analogy often used for structure-based design is that of a lock and key: first understand the type of lock involved, and then design a key to fit that lock. Researchers sought to understand the structure of the molecules that might affect disease processes (the “lock”) and then to design drugs capable of interacting with the target molecules to alter their functions (the “key”). Employees worked in multi-disciplinary teams, combined technologies from biophysics, chemistry and computer science, and applied them to drug discovery and the development of small molecule drugs. As of 2003, Vertex was listed as one of forty worldwide Technology Pioneers by the World Economic Forum, for advancing drug discovery through this approach.
Who is Joshua Boger Dating?
According to our records, Joshua Boger is possibily single & has not been previously engaged. As of December 1, 2023, Joshua Boger’s is not dating anyone.
Relationships Record: We have no records of past relationships for Joshua Boger. You may help us to build the dating records for Joshua Boger!While under Boger’s leadership, the company worked on several potentially valuable drug treatments. Agenerase (amprenavir), an HIV protease inhibitor, was co-developed by Vertex and GlaxoSmithKline for the treatment of HIV/AIDS and approved by the FDA in 1999. A second related drug was submitted for approval in 2002. Lexiva (fosamprenavir) was approved by U.S. regulators on October 20, 2003.
Facts & Trivia
Joshua Ranked on the list of most popular Biochemist. Also ranked in the elit list of famous people born in United States. Joshua Boger celebrates birthday on April 12 of every year.
Boger retired as CEO of Vertex as of May 23, 2009, but remained on the Vertex Board of directors until June 2017. The history of Vertex has been chronicled by journalist Barry Werth in The Billion-Dollar Molecule (1995) and The Antidote.
You may read full biography about Joshua Boger from Wikipedia.
